None of the blood samples contained SARS-CoV-2 antibodies, thus eliminating any antibody-mediated classical pathway activation of complement. C3, C5, and heparan sulfate inhibitors are not capable ...

Acute chest syndrome (ACS), a life-threatening complication of sickle cell disease (SCD), may be driven by overactivation of ...

Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to ...

Similar to bound C1q and anti-RBD IgG, there was a significant correlation between bound C1q and C5b-9, with rs= 0.9, indicating that the classical pathway activation following C1q binding was ...

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway PRESS RELEASE GlobeNewswire Dec. 20, 2023, 05:08 PM ...

To understand the complement system’s involvement in ACS, Stowell and his team assessed the blood of 27 sickle-cell-disease patients experiencing ACS for signs of complement activation.

Persistent complement activation during disease remission in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) may be reflective of disease severity and organ involvement but ...

In the phase 1/2a open-label study, AROC3-1001 (Clinicaltrials.gov; NCT05083364), patients experienced durable reductions in serum C3, complement activity, proteinuria, and hematuria over a 24 ...

RLS-0071 is a 15 amino acid peptide that inhibits both humoral inflammation by blocking classical pathway complement activation and cellular inflammation by blocking the neutrophil effectors ...

“After more than a decade of groundbreaking research targeting the early classical complement pathway, we are excited to have reached an important step in the clinical development of ANX1502 ...